PBRM1 and renal cell carcinoma: reported higher response rates to immune checkpoint inhibitors and significantly prolonged overall survival in renal cell carcinoma patients with PBRM1 mutations, suggesting PBRM1 as a predictive marker for immunotherapy efficacy (16).